Get the Stockscreener App
3.96
0.25%
-0.01
Pre-market:
4.00
0.04
+1.01%
Voyager Therapeutics Inc stock is traded at $3.96, with a volume of 576.53K.
It is down -0.25% in the last 24 hours and up +1.54% over the past month.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
See More
Previous Close:
$3.97
Open:
$3.95
24h Volume:
576.53K
Relative Volume:
0.82
Market Cap:
$236.01M
Revenue:
$40.37M
Net Income/Loss:
$-119.72M
P/E Ratio:
-1.941
EPS:
-2.0402
Net Cash Flow:
$-135.06M
1W Performance:
+2.59%
1M Performance:
+1.54%
6M Performance:
-16.28%
1Y Performance:
+29.41%
1-Day Range:
$3.755
$3.98
1-Week Range:
$3.755
$4.09
52-Week Range:
$2.645
$5.55
Voyager Therapeutics Inc Stock (VYGR) Company Profile
Name
Voyager Therapeutics Inc
Sector
Industry
Phone
857-259-5340
Address
75 HAYDEN AVENUE, LEXINGTON, MA
Compare VYGR vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYGR
Voyager Therapeutics Inc
|
3.96 | 236.01M | 40.37M | -119.72M | -135.06M | -2.0402 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Voyager Therapeutics Inc Stock (VYGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-02-24 | Initiated | Citigroup | Buy |
| Nov-29-24 | Resumed | Wedbush | Outperform |
| Oct-16-24 | Initiated | Leerink Partners | Outperform |
| Mar-26-24 | Initiated | Guggenheim | Buy |
| Mar-19-24 | Initiated | H.C. Wainwright | Buy |
| Mar-07-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| May-10-23 | Initiated | Truist | Buy |
| Mar-10-23 | Initiated | Oppenheimer | Outperform |
| Oct-07-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-03-21 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-03-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-24-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-23-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-10-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-19-20 | Initiated | The Benchmark Company | Buy |
| Feb-06-20 | Initiated | Oppenheimer | Outperform |
| Nov-15-18 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Sep-10-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-18 | Initiated | H.C. Wainwright | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-12-18 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-02-18 | Initiated | Morgan Stanley | Overweight |
| Nov-28-17 | Resumed | Piper Jaffray | Overweight |
| Oct-31-17 | Initiated | Robert W. Baird | Outperform |
| Oct-27-17 | Initiated | Canaccord Genuity | Buy |
| Oct-23-17 | Reiterated | Stifel | Buy |
| Oct-12-17 | Initiated | Raymond James | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-28-17 | Resumed | Stifel | Buy |
View All
Voyager Therapeutics Inc Stock (VYGR) Latest News
If You Invested $1,000 in Voyager Therapeutics Inc (VYGR) - stocktitan.net
VYGR SEC FilingsVoyager Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Voyager Therapeutics CEO Sandrock sells $44,547 in stock By Investing.com - Investing.com Canada
Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $44,547.57 in Stock - MarketBeat
Voyager Therapeutics (VYGR) CEO sells shares for RSU tax withholding - stocktitan.net
Voyager Therapeutics (VYGR) awards 50,000 RSUs to legal chief - stocktitan.net
Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below 50-Day Moving AverageShould You Sell? - MarketBeat
Issuer (NASDAQ: VYGR) Form 144 — 11,511 common shares listed - Stock Titan
Will Voyager Therapeutics Inc stock hit new highs in YEARWeekly Profit Summary & Stock Portfolio Risk Control - baoquankhu1.vn
Voyager Therapeutics (VYGR) price target increased by 12.22% to 17.17 - MSN
Market Overview: Is GCMGW showing insider buying2026 Fundamental Recap & Real-Time Buy Signal Alerts - baoquankhu1.vn
Gap Down: How does Voyager Therapeutics Inc compare to its peersMarket Movement Recap & Weekly Stock Breakout Alerts - baoquankhu1.vn
Returns Recap: Is Voyager Therapeutics Inc subject to activist investor interest2026 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Activity Recap: Is Voyager Therapeutics Inc subject to activist investor interest2026 Price Action Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Vanguard disaggregates holdings after realignment (VYGR) — reports 0% ownership - Stock Titan
Voyager Therapeutics (NASDAQ:VYGR) Stock Rating Upgraded by Truist Financial - Defense World
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Strong-Buy at Truist Financial - marketbeat.com
Short Covering: Can Voyager Therapeutics Inc reach all time highs this year2026 Sector Review & Breakout Confirmation Alerts - baoquankhu1.vn
Citi Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Is Voyager Therapeutics Inc stock a smart retirement pickMarket Trend Review & Breakout Confirmation Alerts - baoquankhu1.vn
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut - Yahoo Finance
Published on: 2026-03-22 03:58:04 - baoquankhu1.vn
HC Wainwright Analysts Increase Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics at Stifel 2026 CNS Forum: Year of Tau Focus - Investing.com Canada
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy By Investing.com - Investing.com Canada
Analysts Set Expectations for VYGR Q1 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR) - The Globe and Mail
Voyager Therapeutics (VYGR): Analyst Reiterates Buy Rating and M - GuruFocus
Voyager Therapeutics' (VYGR) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Truist reiterates Buy on Voyager Therapeutics stock ahead of data By Investing.com - Investing.com Canada
Truist reiterates Buy on Voyager Therapeutics stock ahead of data - Investing.com
Voyager Therapeutics Stock (ISIN: US92916U1025) Eyes Major Upside Amid Gene Therapy Pipeline Momentu - AD HOC NEWS
Voyager Therapeutics (NASDAQ:VYGR) Upgraded to Hold at Wall Street Zen - MarketBeat
Insider Trends: Can Voyager Therapeutics Inc reach all time highs this year - baoquankhu1.vn
Is Voyager Therapeutics (VYGR) Balancing Pipeline Ambition With Sustainable Losses After Its 2025 Results? - simplywall.st
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Yahoo Finance
Guggenheim Remains a Buy on Voyager Therapeutics (VYGR) - The Globe and Mail
Wells Fargo Sticks to Their Buy Rating for Voyager Therapeutics (VYGR) - The Globe and Mail
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Voyager Therapeutics Faces Rising Tariff and U.S.–China Geopolitical Risks as BIOSECURE Act Threatens Key Chinese CDMO Partnerships - The Globe and Mail
Voyager Therapeutics (VYGR) Gets a Buy from H.C. Wainwright - The Globe and Mail
Voyager Therapeutics (VYGR) Q4 Loss Of US$27 Million Reinforces Bearish Profitability Concerns - simplywall.st
Voyager Therapeutics, Inc. 2025 Annual Report: Key Risks, Forward-Looking Statements, and Business Overview - Minichart
Voyager Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com Australia
Voyager Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Voyager Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Voyager Therapeutics Q4 2025 Financial Report: Revenue Surpasses EstimatesNews and Statistics - IndexBox
Voyager Therapeutics Inc Stock (VYGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):